Zhou Q, Wu L, Hu P, An T, et al. A novel third generation EGFR tyrosine kinase inhibitor Abivertinib for EGFR T790M mutant Non-Small Cell Lung Cancer: a multicenter phase1/2 study. Clin Cancer Res 2021 Nov 5. pii: 1078-0432.CCR-21-2595.
PMID: 34740925